CASI Pharmaceuticals Inc. (CASI): Interesting things to know About CASI


CASI Pharmaceuticals Inc. (NASDAQ:CASI) changes shares on Wednesday trading session, with a change of 0.00% or $0.0 shares. The trading starts at $1.92 and closed at $1.92 throughout the day. The trading session low price was $1.85 and day high was $1.94 on Wednesday, August 05. After the session, the Healthcare sector daily volume shifted to 1.25 million while its average volume is 388.53K. In other hand, the CASI market cap reached to $244.22M.

On June 17, 2020, BRIEF-Casi Pharmaceuticals Unit Entered Into Loan Agreement With Juventas Cell Therapy Ltd. According to the news reported on Reuters, * CASI PHARMACEUTICALS – ON JUNE 8, UNIT ENTERED INTO LOAN AGREEMENT WITH JUVENTAS CELL THERAPY LTD

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -5.42% and down -15.42% for month. Its quarterly performance was 15.66% above, while its half year performance is down -27.27%. CASI yearly performance stood at negative -36.84% and fall -37.86% for year-to-date.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. CASI EPS (TTM) for 12-month is -0.48. EPS for this year is -48.00%, while for the next year its value is -0.31. Its EPS Q/Q reached 0.00%. It has an EPS of 12.10% up for past five years.

Let’s take a look on the analyst recommendations on CASI for the current month and previous month. For the current month, 1 of 1 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 0 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $3.50 – $3.50. Average target price for CASI was reached at $3.50.

IDG-Accel China Growth Fund III Associates, LP, Blackrock Inc. and Vanguard Group, Inc. (The) are the top three holders in CASI Pharmaceuticals Inc. (CASI) stock. On Mar 30, 2020, IDG-Accel China Growth Fund III Associates, LP has 7.97 million shares which valued 16.27 million. On Mar 30, 2020, Blackrock Inc. owned 3.25 million shares which valued at 6.63 million. On Mar 30, 2020, Vanguard Group, Inc. (The) has a total of 2.39 million shares which valued at 4.87 million. In the end, Vanguard Group, Inc. (The) have 1.97% shares outstanding of CASI Pharmaceuticals Inc. (CASI) on Mar 30, 2020. The insider ownership moved to 4.00% and institutional holding shifted to 18.60%.

The company posted an EPS (TTM) of -0.48. According to the most recent quarter report on (Jun 2020), 1 analysts estimated an average EPS of -0.08, while -0.16 EPS posted a year ago period. Analyst Estimated EPS for CASI published in the report was -$0.08 – -$0.08 during the same period. Comparing with last year, the average estimated EPS was -0.16 which is lower than -0.09 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for CASI fall -23.63% for period of 200 days. SMA for 50 days was -19.21% which is showing red signal, while SMA-20 was -8.55%. The moving average value for CASI Pharmaceuticals Inc. (CASI) is 1.58M and 1.64% for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in CASI stock. On Jul 22, Zhang Larry, President, bought 20,153 trading shares at the cost of $1.90, which valued at 38291.0. On Jul 22, He Wei-Wu, Chairman and CEO, bought 1,200,000 shares at the cost of $1.90, with total shares of 7,532,347. On Jul 22, He Wei-Wu, Chairman and CEO, bought 2,952,426 shares at the cost of 1.90. After this transaction, He Wei-Wu total shares reached to 4,836,523 which valued at 5.61 million.